Kainova Therapeutics has shared positive early results from their first-stage study of DT-9081, a new oral medicine being developed for patients with advanced or spreading solid tumors. The study, conducted in France and Belgium, achieved all its main goals. DT-9081 showed a good safety profile and promising drug behavior in the body, including effective engagement with its target across all tested doses. There were also early signs that the drug may help shrink tumors. No serious side effects were reported, supporting the drug’s tolerability. More details can be found on clinicaltrials.gov under the identifier NCT05582850. Professor Jean-Pascal Machiels, who led the study, said these results confirm that targeting the EP4 receptor can help fight cancer by boosting the immune system. Dr. Jean-Marie Cuillerot, the company’s medical chief, noted that the study provided clear and useful data about how DT-9081 works in patients. CEO Sean A MacDonald added that these findings highlight the potential of their innovative approach to cancer treatment, offering new hope for patients with advanced solid tumors.